TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius engineers. Gregg Higgs is owner of Fab Fours, a car accessory manufacturer that has ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the ...

A month has gone by since the last earnings report for Kymera Therapeutics, Inc. (KYMR). Shares have added about 10.9% in that time frame, outperforming the S&P 500.

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi.

Gilead to pay Kymera up to $750 million for CDK2 degrader program; upfront and option payments total up to $85 million. PPI and Industrial Production drop Wednesday morning — see how Matt Maley ...

Gilead Sciences partners with Kymera Therapeutics in a $750 million deal to develop molecular glue degraders for breast cancer treatment. San Francisco Business Times. Select a City ...

Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering.

In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price per share, less ...

Kymera Therapeutics reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent succeeded in a closely watched early-stage trial.